Navigation Links
Pfizer Whistleblower Named Year's Most Influential Person In Business Ethics
Date:12/18/2009

WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- John Kopchinski, the whistleblower whom Phillips & Cohen LLP represented in a successful, record-setting "qui tam" case against Pfizer Inc., has been named as the most influential person in business ethics for 2009.

Ethisphere, a think tank that focuses on business ethics, corporate social responsibility, anti-corruption and sustainability, compiles an annual list of the 100 most influential people in business ethics. The group named Kopchinski number one on its 2009 list.

A former sales representative for Pfizer, Kopchinski exposed the company's illegal sales and marketing campaign for the prescription painkiller Bextra for uses and in doses that endangered patients' health and lives. (See http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements531.asp)

Pfizer paid $1.8 billion in September to the government to settle Kopchinski's qui tam lawsuit and a related criminal charge. The company settled four other whistleblower lawsuits at the same time, bringing the total settlement to $2.3 billion. It was the largest healthcare fraud settlement ever and the largest criminal fine ever imposed in the U.S.

"John Kopchinski wasn't seen as a team player and ultimately lost his job at Pfizer," said Erika Kelton, a Washington, DC, attorney with Phillips & Cohen. "But the happy ending to his story and the recognition this honor bestows should give other whistleblowers hope."

Kopchinski "officially turned whistleblowing into big business," said Ethisphere. He received more than $70 million as a reward for the work he and his attorneys did on the Pfizer case. The False Claims Act requires the government to award whistleblowers a percentage of the funds the government recovers as a result of their qui tam cases.

Phillips & Cohen specializes in representing whistleblowers in cases involving fraud against the government, tax matters and securities violations. Cases brought by the firm's attorneys have recovered more than $5.3 billion in civil and criminal penalties for the government. For more information about whistleblowers and qui tam cases, see www.phillipsandcohen.com.

For more information about the Pfizer qui tam case and settlement, see http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements536.asp

SOURCE Phillips & Cohen LLP


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced ... ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of ... Tribute. The combined company will operate under Aralez Pharmaceuticals ... in Canada , Ireland ... . Under the terms of the Agreement and Plan ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
(Date:2/5/2016)... February 4, 2016 France , ... , UK, and Israel ). It includes a ... and 3 GD, segmented by age and sex in these markets. GD ... EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis ... , Germany , Italy , ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s leading ... Big Game. Take the stress out of your party preparation – follow these easy, ... every stage of the game. , “The key to hosting a successful game-day party ...
(Date:2/5/2016)... ... 2016 , ... At its annual meeting held last week, the American Parkinson ... Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are ... , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he ...
Breaking Medicine News(10 mins):